Lyon University, Oullins, France.
J Nutr Biochem. 2013 Feb;24(2):457-66. doi: 10.1016/j.jnutbio.2012.01.008. Epub 2012 May 30.
Type 2 diabetes is a complex disease characterized by a state of insulin resistance in peripheral tissues such as skeletal muscle, adipose tissue or liver. Some inositol isomers have been reported to possess insulin-mimetic activity and to be efficient in lowering blood glucose level. The aim of the present study was to assess in mice the metabolic effects of a chronic treatment with myo-inositol, the most common stereoisomer of inositol. Mice given myo-inositol treatment (0.9 or 1.2 mg g(-1) day(-1), 15 days, orally or intraperitoneally) exhibited an improved glucose tolerance due to a greater insulin sensitivity. Mice treated with myo-inositol exhibited a decreased white adipose tissue accretion (-33%, P<.005) compared with controls. The decrease in white adipose tissue deposition was due to a decrease in adipose cell volume (-33%, P<.05), while no change was noticed in total adipocyte number. In skeletal muscle, in vivo as well as ex vivo myo-inositol treatment increased protein kinase B/Akt phosphorylation under baseline and insulin-stimulated conditions, suggesting a synergistic action of myo-inositol treatment and insulin on proteins of the insulin signalling pathway. Myo-inositol could therefore constitute a viable nutritional strategy for the prevention and/or treatment of insulin resistance and type 2 diabetes.
2 型糖尿病是一种复杂的疾病，其特征是外周组织（如骨骼肌、脂肪组织或肝脏）存在胰岛素抵抗状态。一些肌醇异构体已被报道具有胰岛素模拟活性，并能有效降低血糖水平。本研究旨在评估肌醇（最常见的肌醇立体异构体）在慢性治疗小鼠中的代谢作用。给予肌醇治疗的小鼠（0.9 或 1.2mg g(-1)天(-1)，口服或腹膜内 15 天）表现出改善的葡萄糖耐量，这是由于胰岛素敏感性增加所致。与对照组相比，肌醇治疗的小鼠白色脂肪组织积累减少（-33%，P<.005）。白色脂肪组织沉积的减少归因于脂肪细胞体积的减少（-33%，P<.05），而总脂肪细胞数量没有变化。在骨骼肌中，体内和体外肌醇治疗在基础和胰岛素刺激条件下均增加蛋白激酶 B/Akt 的磷酸化，提示肌醇治疗和胰岛素对胰岛素信号通路蛋白具有协同作用。因此，肌醇可以成为预防和/或治疗胰岛素抵抗和 2 型糖尿病的可行营养策略。
